Sorrento Therapeutics (LTS:0L85) EBIT: $-546.05 Mil (TTM As of Jun. 2023)

What is Sorrento Therapeutics EBIT?

Sorrento Therapeutics LTS:0L85 12 EBIT is $-546.05 Mil as of Jun. 2023. GuruFocus rates LTS:0L85 with a GF Score™ of 12/100.

Sorrento Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was $-105.20 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was $-546.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sorrento Therapeutics's annualized ROC % for the quarter that ended in Jun. 2023 was -69.61%. Sorrento Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -340.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sorrento Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -427.29%.

Sorrento Therapeutics (LTS:0L85) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sorrento Therapeutics's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-307.068 * ( 1 - 0% )	/	( (424.028	+	458.162)	/ 2 )
=	-307.068	/	441.095
=	-69.61 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	460.063	-	100.907	-	( 50.317	-	max(0, 165.632	-	100.76	+	50.317	))
=	424.028

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	456.692	-	130.368	-	( 80.635	-	max(0, 264.949	-	133.111	+	80.635	))
=	458.162

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Sorrento Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-420.788	/	( ( (140.259 + max(-51.504, 0))	+	(106.645 + max(-79.06, 0)) )	/	2 )
=	-420.788	/	( ( 140.259	+	106.645 )	/	2 )
=	-420.788	/	123.452
=	-340.85 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(26.524	+	11.308	+	12.611)	-	(100.907	+	0.252	+	0.78800000000001)
=	-51.504

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(32.725	+	9.651	+	10.1)	-	(130.368	+	0.256	+	0.91200000000003)
=	-79.06

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sorrento Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-546.045	/	127.792
	=	-427.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics EBIT Related Terms

Sorrento Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Sorrento Therapeutics's EBIT can be seen below:

Sorrento Therapeutics EBIT Chart

Sorrento Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-156.15

-324.53

-290.42

-452.30

-553.17

Sorrento Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBIT	Get a 7-Day Free Trial															-218.29	-90.91	-208.28	-141.66	-105.20

LTS:0L85 vs IMUX, OCUP, KZR: EBIT Comparison

For the Biotechnology subindustry, Sorrento Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sorrento Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's EV-to-EBIT falls into.

Save Embed

12GF Score

Sorrento Therapeutics Inc LTS:0L85

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sorrento Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-546.05 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-546.05 Mil mean?

Sorrento Therapeutics (LTS:0L85) has a EBIT of $-546.05 Mil as of Jun. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sorrento Therapeutics.

Is Sorrento Therapeutics' EBIT too high?

Sorrento Therapeutics' current EBIT is $-546.05 Mil. Overall, Sorrento Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Sorrento Therapeutics' EBIT compare to IMUX and OCUP?

Sorrento Therapeutics' EBIT of $-546.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sorrento Therapeutics. Sorrento Therapeutics's current EBIT is $-546.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sorrento Therapeutics stock overvalued right now?

Sorrento Therapeutics (LTS:0L85) has a current EBIT of $-546.05 Mil. The current EBIT is $-546.05 Mil. Sorrento Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Sorrento Therapeutics (LTS:0L85), the current EBIT is $-546.05 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sorrento Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies IMUX OCUP KZR HRGN CRDF SABS CDTX NGM KRON MNOV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY

Address 4955 Directors Place, San Diego, CA, USA, 92121

Website https://www.sorrentotherapeutics.com

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

12GF Score

Get the complete analysis for LTS:0L85

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View LTS:0L85 Analysis

See EBIT data for all stocks →